Pertuzumab Suppliers & Bulk Manufacturers
Available Forms: Solution for IV infusion
Available Strengths: 420 mg/14 mL
Reference Brands: Perjeta (USA/EU), Pertuza (India), Herticad (India)
Category:
Oncology Cancer Care
Pertuzumab is available in Solution for IV infusion
and strengths such as 420 mg/14 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pertuzumab is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pertuzumab can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer, a type of cancer that produces higher levels of the human epidermal growth factor receptor 2 (HER2) protein. This protein promotes the growth and spread of cancer cells. Pertuzumab works by specifically targeting the HER2 receptor and blocking signals that stimulate tumor cell growth. By interfering with these signaling pathways, the medicine helps slow down or stop the progression of cancer.
Pertuzumab is commonly used in combination with other cancer treatments, particularly trastuzumab and the chemotherapy drug docetaxel. This combination therapy is widely used for patients with metastatic HER2-positive breast cancer, where the disease has spread to other parts of the body. In addition to treating advanced disease, pertuzumab is also used as a neoadjuvant treatment in early HER2-positive breast cancer. In this setting, it is given before surgery to help shrink tumors and improve treatment outcomes.
As a targeted biological therapy, pertuzumab plays an important role in modern oncology by providing a more precise treatment approach for patients whose tumors overexpress the HER2 protein. Its use in combination regimens has significantly improved clinical outcomes for many patients with HER2-positive breast cancer.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing